埃博拉疫苗市场规模，[按产品（重组囊泡口炎病毒 - Zaire Ebola病毒，黑猩猩腺瘤病毒3- Zaire Ebola病毒，腺瘤病毒血清型26- Zaire Ebola病毒）]]和地理 - 趋势，分析和预测直到2025年

Report Summary

全球埃博拉疫苗市场规模预计预计预测期内的显着增长主要是埃博拉病毒准确治疗疫苗的不可用。埃博拉，也称为埃博拉出血热是埃博拉病毒属内存在的危及生命的病毒感染之一。埃博拉被当前年龄作为男子气概的主要风险。通常，病毒蔓延到动物中。此外，感染者与体液直接接触是该病毒传播的主要原因之一。最近在西非的埃博拉袭击事件发生了全球焦点的疾病。非洲国家，如塞拉利昂，刚果民主共和国，塞内加尔，马里，尼日利亚和西伯利亚的国家受到埃博拉病毒的影响。此外，由于埃博拉，2014 - 2016年，豚鼠，leone和西伯利亚等西非国家的死亡病例约为11,300。

Ebola starts out as a heavy fever, muscle pain, severe headache, body ache and sore throat. It is a viral hemorrhagic fever, a condition in which the patient bleeds externally as well as internally. The lack of a consistent cure for Ebola virus is the primary goal for the market players and investors of the Ebola treatment. Although, there is no cure for Ebola virus disease, characteristic diagnosis and treatment such as maintaining treating the infectious condition of the virus, constant visualization of required oxygen level, and electrolyte balance might help in improving patient’s health. Most of the vaccines to prevent Ebola virus disease are under the different developmental stage.

在某些地区担心潜在爆发EVD和对新型疫苗的巨大需求预计会提高埃博拉疫苗市场规模增长。

全球埃博拉疫苗市场规模主要受到缺乏保证解决方案目前的影响因素的驱动。埃博拉的冲动性也有助于投资者和关键参与者将其研发结构大规模增加，因为病毒的病因和病理生理学是未知的。这个因素将大大增加全球埃博拉疫苗市场。此外，由于以前的非洲国家案件提高了人们利益使用疫苗的兴趣。此外，2017年5月，世界卫生组织（WHO）承认刚果民主共和国埃博拉病毒疾病的爆发。仍然害怕和恐慌在西非经济中的埃博拉病毒可能爆发。各种机构和制药公司专注于开发针对EVD的疫苗。因此，在该地区的意识也是这些区域中埃博拉疫苗市场规模的增长的因素。加强全球市场的另一个因素是由于对埃博拉疫苗的政府支持稳定，对埃博拉疫苗的新兴需求也成为制药公司的商业盈利。

However, unawareness for the availability of vaccines and the cost associated with the vaccines is the factor restraining the global market growth. Moreover, due to unpredictable nature of the virus, the risk of producing a resistance of Ebola virus for the vaccine is anticipated to hinder the Ebola vaccines market growth.

Global Ebola Vaccines Market Taxonomy:

The global Ebola vaccines market is segmented on the basis of virus strain and geography.

在病毒菌株的基础上，全球埃博拉疫苗市场被分段为：

• 重组囊泡口炎病毒 - 扎伊尔埃博拉病毒
• Chimpanzee Adeno virus type 3-Zaire Ebola virus
• adeno病毒血清型26-扎伊尔埃博拉病毒

Geographically, the global Ebola vaccines market is segmented into North America, Europe, Asia pacific, Latin America, Middle East, and Africa.

North America to dominate the global Ebola Vaccines market size, yet the Middle East and Africa to generate lucrative opportunities due to fear of outburst the Ebola virus disease.

On the basis geography, the Middle East and Africa are estimated to form lucrative opportunities for the global Ebola Vaccines market size owing to the high prevalence of Ebola infection cases in this region. However, North America is estimated to dominate the global Ebola vaccines market. The global market is driven by the advanced medical research scenario in the U.S. is the primary reason for the regional growth in the global market. However, Asia Pacific is anticipated to show dominating market growth due to government initiatives to make people aware to use Ebola vaccines and improved healthcare infrastructure.

Key players of global Ebola vaccines market:

• Tekmira Pharmaceuticals
• Serepata Therapeutics
• mapp生物制药
• NewLink Genetics Corp.
• Biocryst Pharmaceutical Inc.

Several key players and investors are focusing on producing vaccines for Ebola vaccine, enhancing their global presence. For instance, according to the Lancet, a published journal 2016, rVSV-ZEBOV called as V920 vaccine, developed by Newlink Genetics and Merck, which is found to be operative for phase III trial to cure Ebola virus disease. rVSV-ZEBOV uses strains of Zaire Ebola virus. The company has produced approximately 300,000 vaccines, in case of a fresh outbreak in vulnerable regions and applied for USFDA clearance. Moreover, GlaxoSmithKline has manufactured CAd3-ZEBOV vaccine which is derived using strains of chimpanzee adenovirus. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary rDNA technology.